SPOTLIGHT: Vasogen shares slide on trial results

Shares of Vasogen slid on news that a Phase III trial of Celacade failed to improve the walking range of patients with arterial disease. The Toronto-based developer, though, said that the data indicating Celacade may reduce inflammation that leads to heart ailments was the most important result of the trial. Report